Patents by Inventor Yewei Sun
Yewei Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12187688Abstract: A crystal form of tetramethylpyrazine nitrone (TBN), and a preparation method and use thereof is provided. A crystal form A of TBN has characteristic diffraction peaks in the XRPD pattern at 2?°: 10.60±0.2, 11.03±0.2, 15.31±0.2, 15.55±0.2, 17.14±0.2, 17.93±0.2, and 23.81±0.2. The crystal form A has low risk of polymorphism transformation and good stability, which contribute to the stability of the preparations during the production and storage processes, and effectively guarantee the consistency of the content of the crystal form in the preparations. Therefore, the preparations are safe, effective, and controllable in quality. Also, the crystal form A has high biological activity, good druggability, and high bioavailability, fast onset of action.Type: GrantFiled: July 31, 2019Date of Patent: January 7, 2025Assignee: GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD.Inventors: Wei Liu, Yewei Sun, Yuqiang Wang
-
Patent number: 11903923Abstract: The present invention provides uses of an andrographolide derivative in preparation of a medicament for preventing and treating inflammatory bowel disease. The andrographolide derivative AL-1 has the mechanisms, for the treatment of ulcerative colitis, of scavenging of free radicals, inhibition of NF-?B signaling pathway activation and COX-2 expression, activation of PPAR-? expression, and thus can prevent the transcription and expression of inflammatory-related genes to improve the conditions of inflammation. AL-1 can be used as a medicine for the treatment of inflammatory bowel disease and can be formulated to various dosage forms with a pharmaceutically acceptable carrier.Type: GrantFiled: July 4, 2016Date of Patent: February 20, 2024Inventors: Yuqiang Wang, Lipeng Xu, Pei Yu, Yewei Sun, Zaijun Zhang, Gaoxiao Zhang, Peng Yi
-
Publication number: 20220371987Abstract: The present invention provided a process for manufacture of amantadine nitrate derivatives, and the process comprises using adamantane as the raw material to prepare amantadine nitrate derivatives via the following steps: (1) synthesis of adamantanol; (2) carboxylation of adamantanol; (3) acetylation of adamantanoic acid; (4) reduction; (5) hydrolysis of amido adamantanol and Boc protection of amino group; (6) crystallization of Boc protected amantadinol; (7) nitrate esterification of Boc protected amantadinol; (8) refining of the product of nitrate esterification; (9) Boc deprotection and salt formation; and (10) refining of amantadine nitrate hydrochloride. The amantadine nitrate derivatives have the struction of: wherein, R1 and R2 are each independently hydrogen, straight-chain or branched-chain alkyl, or substituted or unsubstituted aryl or heteroaryl. The process of this invention is efficient, cost effective, environmentally friendly, safe, reliable, and suitable for industrial production.Type: ApplicationFiled: September 11, 2019Publication date: November 24, 2022Applicant: QINGDAO HAILAN PHARMACEUTICALS CO., LTD.Inventors: Yuqiang WANG, Zheng LIU, Yewei SUN, Zaijun ZHANG, Gaoxiao ZHANG
-
Publication number: 20220202812Abstract: The present invention relates to the use of ligustrazine nitrone derivatives and pharmaceutical composition thereof for the treatment and prevention of diseases of diabetic complications, which include renal anemia. The ligustrazine nitrone derivatives have the structure of the general formula (I). Experimental results indicated that the ligustrazine nitrone derivatives can significantly increase the levels of serum iron and erythropoietin in STZ induced SD rats and spontaneously hypertensive rats, and can be used for treating and preventing renal anemia caused by decrease in renal EPO production and/or concomitant iron deficiency. Therefore, the ligustrazine nitrone derivatives can be made into various dosage forms with a drug carrier. The derivatives can be prepared into various dose forms together with drug carriers.Type: ApplicationFiled: November 3, 2021Publication date: June 30, 2022Applicant: QINGDAO HAILAN PHARMACEUTICALS CO., LTD.Inventors: Yuqiang Wang, Yewei Sun, Lipeng Xu, Mei Jing, Zaijun Zhang, Gaoxiao Zhang, Pei Yu, Peng Yi
-
Publication number: 20220168299Abstract: The present invention discloses a pharmaceutical composition comprising TBN, or a salt or a hydrate thereof, and a preparation method therefor. The pharmaceutical composition comprises (1) a tablet core comprising the active ingredient TBN or a pharmaceutically acceptable salt or hydrate thereof and an alkalizing agent; and (2) an enteric layer outside the tablet core, comprising an opaquer and a coating material. The pharmaceutical composition has the enteric layer with good film-forming ability, which improves the bioavailability of TBN in the body; and is useful in the treatment of diseases caused by overproduction of free radicals/thrombosis in clinic.Type: ApplicationFiled: July 31, 2019Publication date: June 2, 2022Applicant: GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD.Inventors: Wei LIU, Yewei SUN, Yuqiang WANG
-
Publication number: 20220153707Abstract: A crystal form of tetramethylpyrazine nitrone (TBN), and a preparation method and use thereof is provided. A crystal form A of TBN has characteristic diffraction peaks in the XRPD pattern at 2?°: 10.60±0.2, 11.03±0.2, 15.31±0.2, 15.55±0.2, 17.14±0.2, 17.93±0.2, and 23.81±0.2. The crystal form A has low risk of polymorphism transformation and good stability, which contribute to the stability of the preparations during the production and storage processes, and effectively guarantee the consistency of the content of the crystal form in the preparations. Therefore, the preparations are safe, effective, and controllable in quality. Also, the crystal form A has high biological activity, good druggability, and high bioavailability, fast onset of action.Type: ApplicationFiled: July 31, 2019Publication date: May 19, 2022Applicant: GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD.Inventors: Wei LIU, Yewei SUN, Yuqiang WANG
-
Patent number: 11197855Abstract: A use of of ligustrazine nitrone derivatives and a pharmaceutical composition thereof in the preparation of medicine for preventing and treating diabetic complication diseases. The ligustrazine nitrone derivatives can be prepared into various dose forms together with drug carriers.Type: GrantFiled: May 25, 2018Date of Patent: December 14, 2021Inventors: Yuqiang Wang, Yewei Sun, Lipeng Xu, Mei Jing, Zaijun Zhang, Gaoxiao Zhang, Pei Yu, Peng Yi
-
Patent number: 11161800Abstract: The present invention relates to amantadine nitrate compounds having neural protective effect, and preparation method and medical use thereof. The compounds have the structure of the general formula (II). The compounds have multifunctional mechanisms, including inhibiting NMDA receptors, releasing NO, inhibiting calcium influxes, and having protective effects on cells particularly neurocytes. The compounds can be used in the preparation of medicaments having a cellular protective effect, for prevention or treatment of the diseases related to such as NMDA receptors and elevation of calcium anions in cells, including the diseases related to neurodegeneration such as Alzheimer's disease, Parkinson's disease, cerebral paralysis and glaucoma, and the diseases related to cardio-cerebral-vascular system such as Parkinson's syndrome combined with cerebral arteriosclerosis, as well as respiratory tract infections caused by influenza virus.Type: GrantFiled: December 20, 2018Date of Patent: November 2, 2021Inventors: Yuqiang Wang, Zheng Liu, Pei Yu, Yewei Sun, Zaijun Zhang, Gaoxiao Zhang, Luchen Shan, Peng Yi, James Larrick
-
Patent number: 10703729Abstract: The present invention relates to a pyrazine derivative, and preparation method and medical use thereof. The pyrazine derivative can remove free radicals and suppress calcium overload and has cytoprotective effects, and can be used for the prevention and treatment of cardiovascular and cerebrovascular diseases, neurodegenerative diseases and other related diseases.Type: GrantFiled: July 4, 2016Date of Patent: July 7, 2020Inventors: Yuqiang Wang, Pei Yu, Yewei Sun, Luchen Shan, Gaoxiao Zhang, Zaijun Zhang, Peng Yi
-
Patent number: 10703730Abstract: The present invention relates to trifluoroacetyl hydrazide compounds and medical uses thereof. The compounds have a structure of the following formula: The compounds showed multifunctional mechanisms, including inhibition of glutamate excitotoxicity, activation of MEF2 transcriptional activity, clearance of free radicals, and promotion of nerve differentiation, and has a better protective effect on cells especially nerve cells. The compound can be used to prepare prophylactic or therapeutic medicaments with cytoprotective effects, for the prevention or treatment of diseases related to glutamate receptor activation, MEF2 disorders or excessive free radicals generation. The diseases include, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson and stroke, and the free radicals related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases.Type: GrantFiled: March 19, 2019Date of Patent: July 7, 2020Inventors: Yuqiang Wang, Haiyun Chen, Zaijun Zhang, Gaoxiao Zhang, Pei Yu, Yewei Sun, Luchen Shan, Liang Tao
-
Publication number: 20200155548Abstract: A use of of ligustrazine nitrone derivatives and a pharmaceutical composition thereof in the preparation of medicine for preventing and treating diabetic complication diseases. The ligustrazine nitrone derivatives can be prepared into various dose forms together with drug carriers.Type: ApplicationFiled: May 25, 2018Publication date: May 21, 2020Applicant: QINGDAO HAILAN PHARMACEUTICALS CO., LTD.Inventors: Yuqiang Wang, Yewei Sun, Lipeng Xu, Mei Jing, Zaijun Zhang, Gaoxiao Zhang, Pei Yu, Peng Yi
-
Publication number: 20190276413Abstract: The present invention relates to a pyrazine derivative, and preparation method and medical use thereof. The pyrazine derivative can remove free radicals and suppress calcium overload and has cytoprotective effects, and can be used for the prevention and treatment of cardiovascular and cerebrovascular diseases, neurodegenerative diseases and other related diseases.Type: ApplicationFiled: July 4, 2016Publication date: September 12, 2019Applicant: GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD.Inventors: Yuqiang WANG, Pei YU, Yewei SUN, Luchen SHAN, Gaoxiao ZHANG, Zaijun ZHANG, Peng YI
-
Publication number: 20190218192Abstract: The present invention relates to trifluoroacetyl hydrazide compounds and medical uses thereof. The compounds have a structure of the following formula: The compounds showed multifunctional mechanisms, including inhibition of glutamate excitotoxicity, activation of MEF2 transcriptional activity, clearance of free radicals, and promotion of nerve differentiation, and has a better protective effect on cells especially nerve cells. The compound can be used to prepare prophylactic or therapeutic medicaments with cytoprotective effects, for the prevention or treatment of diseases related to glutamate receptor activation, MEF2 disorders or excessive free radicals generation. The diseases include, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson and stroke, and the free radicals related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases.Type: ApplicationFiled: March 19, 2019Publication date: July 18, 2019Applicant: GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD.Inventors: Yuqiang Wang, Haiyun Chen, Zaijun Zhang, Gaoxiao Zhang, Pei Yu, Yewei Sun, Luchen Shan, Liang Tao
-
Publication number: 20190202772Abstract: The present invention relates to amantadine nitrate compounds having neural protective effect, and preparation method and medical use thereof. The compounds have the structure of the general formula (II). The compounds have multifunctional mechanisms, including inhibiting NMDA receptors, releasing NO, inhibiting calcium influxes, and having protective effects on cells particularly neurocytes. The compounds can be used in the preparation of medicaments having a cellular protective effect, for prevention or treatment of the diseases related to such as NMDA receptors and elevation of calcium anions in cells, including the diseases related to neurodegeneration such as Alzheimer's disease, Parkinson's disease, cerebral paralysis and glaucoma, and the diseases related to cardio-cerebral-vascular system such as Parkinson's syndrome combined with cerebral arteriosclerosis, as well as respiratory tract infections caused by influenza virus.Type: ApplicationFiled: December 20, 2018Publication date: July 4, 2019Applicant: GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD.Inventors: Yuqiang WANG, Zheng LIU, Pei YU, Yewei SUN, Zaijun ZHANG, Gaoxiao ZHANG, Luchen SHAN, Peng YI, James LARRICK
-
Patent number: 10308616Abstract: The present invention relates to trifluoroacetyl hydrazide compounds and methods of preparation and uses thereof. The compounds have a structure of the following formula: The compounds showed multifunctional mechanisms, including inhibition of glutamate excitotoxicity, activation of MEF2 transcriptional activity, clearance of free radicals, and promotion of nerve differentiation, and has a better protective effect on cells especially nerve cells. The compound can be used to prepare prophylactic or therapeutic medicaments with cytoprotective effects, for the prevention or treatment of diseases related to glutamate receptor activation, MEF2 disorders or excessive free radicals generation. The diseases include, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson and stroke, and the free radicals related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases.Type: GrantFiled: August 11, 2015Date of Patent: June 4, 2019Inventors: Yuqiang Wang, Haiyun Chen, Zaijun Zhang, Gaoxiao Zhang, Pei Yu, Yewei Sun, Luchen Shan, Liang Tao
-
Patent number: 10214478Abstract: The present invention relates to amantadine nitrate compounds having neural protective effect, and preparation method and medical use thereof. The compounds have the structure of the general formula (I). The compounds have multifunctional mechanisms, including inhibiting NMDA receptors, releasing NO, inhibiting calcium influxes, and having protective effects on cells particularly neurocytes. The compounds can be used in the preparation of medicaments having a cellular protective effect, for prevention or treatment of the diseases related to such as NMDA receptors and elevation of calcium anions in cells, including the diseases related to neurodegeneration such as Alzheimer's disease, Parkinson's disease, cerebral paralysis and glaucoma, and the diseases related to cardio-cerebral-vascular system such as Parkinson's syndrome combined with cerebral arteriosclerosis, as well as respiratory tract infections caused by influenza virus.Type: GrantFiled: November 28, 2016Date of Patent: February 26, 2019Inventors: Yuqiang Wang, Zheng Liu, Pei Yu, Yewei Sun, Zaijun Zhang, Gaoxiao Zhang, Luchen Shan, Peng Yi, James Larrick
-
Publication number: 20180346430Abstract: The present invention relates to trifluoroacetyl hydrazide compounds and methods of preparation and uses thereof. The compounds have a structure of the following formula: The compounds showed multifunctional mechanisms, including inhibition of glutamate excitotoxicity, activation of MEF2 transcriptional activity, clearance of free radicals, and promotion of nerve differentiation, and has a better protective effect on cells especially nerve cells. The compound can be used to prepare prophylactic or therapeutic medicaments with cytoprotective effects, for the prevention or treatment of diseases related to glutamate receptor activation, MEF2 disorders or excessive free radicals generation. The diseases include, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson and stroke, and the free radicals related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases.Type: ApplicationFiled: August 11, 2015Publication date: December 6, 2018Applicant: GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD.Inventors: Yuqiang WANG, Haiyun CHEN, Zaijun ZHANG, Gaoxiao ZHANG, Pei YU, Yewei SUN, Luchen SHAN, Liang TAO
-
Publication number: 20180148404Abstract: The present invention relates to amantadine nitrate compounds having neural protective effect, and preparation method and medical use thereof. The compounds have the structure of the general formula (I). The compounds have multifunctional mechanisms, including inhibiting NMDA receptors, releasing NO, inhibiting calcium influxes, and having protective effects on cells particularly neurocytes. The compounds can be used in the preparation of medicaments having a cellular protective effect, for prevention or treatment of the diseases related to such as NMDA receptors and elevation of calcium anions in cells, including the diseases related to neurodegeneration such as Alzheimer's disease, Parkinson's disease, cerebral paralysis and glaucoma, and the diseases related to cardio-cerebral-vascular system such as Parkinson's syndrome combined with cerebral arteriosclerosis, as well as respiratory tract infections caused by influenza virus.Type: ApplicationFiled: November 28, 2016Publication date: May 31, 2018Applicant: Guangzhou Magpie Pharmaceuticals Co., Ltd.Inventors: Yuqiang Wang, Zheng Liu, Pei Yu, Yewei Sun, Zaijun Zhang, Gaoxiao Zhang, Luchen Shan, Peng Yi, James Larrick
-
Publication number: 20180147181Abstract: The present invention provides uses of an andrographolide derivative in preparation of a medicament for preventing and treating inflammatory bowel disease. The andrographolide derivative AL-1 has the mechanisms, for the treatment of ulcerative colitis, of scavenging of free radicals, inhibition of NF-?B signaling pathway activation and COX-2 expression, activation of PPAR-? expression, and thus can prevent the transcription and expression of inflammatory-related genes to improve the conditions of inflammation. AL-1 can be used as a medicine for the treatment of inflammatory bowel disease and can be formulated to various dosage forms with a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 4, 2016Publication date: May 31, 2018Applicant: GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD.Inventors: Yuqiang Wang, Lipeng Xu, Pei Yu, Yewei Sun, Zaijun Zhang, Gaoxiao Zhang, Peng Yi
-
Patent number: 9938235Abstract: The invention generally relates to compounds of formula (I) with neural protective effect, and preparation and uses thereof. The compounds have multiple mechanisms or functions, for example, inhibition of monoamine oxidase and cholinesterase, scavenging of free radicals, and protection of cells such as nerve cells. The compounds can be used for manufacture of medicaments of cell protection, for prevention and/or treatment of monoamine oxidase, cholinesterase and free radicals related diseases, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, and free-radical related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases.Type: GrantFiled: March 2, 2015Date of Patent: April 10, 2018Inventors: Yuqiang Wang, Moussa B. H. Youdim, Yewei Sun, Zaizun Zhang, Gaoxiao Zhang, Pei Yu, Peng Yi, Ming Lang, Wei Liu